-+ 0.00%
-+ 0.00%
-+ 0.00%

Nasus Pharma's NS002 Reaches Therapeutic Epinephrine Threshold Faster Than Autoinjector in Phase 2 Trial

PUBT·11/17/2026 13:03:59
Listen to the news
Nasus Pharma's NS002 Reaches Therapeutic Epinephrine Threshold Faster Than Autoinjector in Phase 2 Trial
  • Nasus Pharma presented Phase 2 NP007 results for investigational anaphylaxis treatment NS002 at ACAAI's annual meeting, held November 12-16, 2026.
  • The intranasal epinephrine powder reached therapeutic levels faster than an autoinjector with both single and repeat dosing.
  • Results also suggested potential superiority over the autoinjector under severe nasal congestion.
  • No serious adverse events were observed.
  • A pivotal study is planned to begin before year-end 2026, with topline results expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170800PRIMZONEFULLFEED9878919) on November 17, 2026, and is solely responsible for the information contained therein.